Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.

Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted to subgroups of patients, and peripheral toxicity. Heptyl physostigmine is a lipophilic carbamate derivative of physostigmine. In rhesus...

Full description

Bibliographic Details
Main Authors: Rupniak, N, Tye, S, Brazell, C, Heald, A, Iversen, S, Pagella, P
Format: Journal article
Language:English
Published: 1992